Infusions of anti-HIV antibodies delayed the resurgence of the virus after standard triple-drug therapy was stopped, a researcher said here.
The delay, compared with that experienced by patients given a placebo, was modest but statistically significant, according to Trevor Crowell, MD, of the U.S. Military HIV Research Program in Bethesda, Md.
But experts here at the International AIDS Society (IAS) meeting on HIV science regard the finding as a promising start for clinical research into what are called broadly neutralizing antibodies, or bNAbs — engineered substances that can kill many strains of HIV.
